Focus:
Central Nervous System
-
20 March 2020 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
6 March 2020 projects
Audentes’ Gene Therapy Manufacturing Facility, Sanford, North Carolina
Audentes Therapeutics, a genetic medicines company, is planning to build a gene therapy manufacturing facility in Sanford, North Carolina, US.
-
4 March 2020 Analysis
A resolution for the new decade: resolve the US opioid crisis
In 2019, the opioid crisis in the US reached its peak. It dominated the news and legislative agenda and two pharma companies declared bankruptcy as a result of multiple legal...
-
28 February 2020 News
Biogen and Sangamo to develop neurological disease drugs
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
-
25 February 2020 Comment
Higher prevalence of epilepsy in low and middle-income countries
Epilepsy is a common neurological condition where abnormal activity in the brain leads to seizures. This condition is usually diagnosed after a person has experienced two or more unprovoked seizures....
-
11 February 2020 Company News
Lilly and Genentech announce two failures in Alzheimer’s disease prevention study
Eli Lilly has announced its drug solanezumab failed to meet its primary endpoint in the Phase II/III Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study.
-
5 February 2020 Analysis
Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the dead
Despite halting development after disappointing trial findings in March, Biogen now plans to submit Alzheimer’s candidate aducanumab for FDA approval, after new analysis showed the drug just might work. Natalie...
-
7 January 2020 News
MHRA grants licence update for Ipsen’s Dysport
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Ipsen’s Dysport.
-
20 December 2019 News
Janssen’s esketamine nasal spray approved in the EU
The European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray for treatment-resistant major depressive disorder.
-
9 December 2019 Research Reports
Huge unmet needs in glioblastoma multiforme market drives the future, says GlobalData
Glioblastoma multiforme (GBM), also known as Grade IV astrocytoma, is the most aggressive form of brain cancer and has one of the highest unmet needs in the oncology market. The...